Online financial news

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company’s Ostarine™ and Capesaris™ clinical development programs.

“We continue to make progress with our clinical development programs”

“We continue to make progress with our clinical development programs,” said Dr. Mitchell S. Steiner, CEO of GTx. “We have recently commenced the POWER1 and POWER2 Phase III clinical trials evaluating Ostarine for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. These studies are designed to demonstrate that Ostarine treatment compared to placebo in patients with non-small cell lung cancer receiving chemotherapy will maintain muscle mass, improve physical function, and possibly even prolong survival.”

Dr. Steiner continued: “We are currently evaluating Capesaris for both first line hormonal and second line hormonal treatment of advanced prostate cancer. For first line hormonal therapy, two Phase II clinical trials are in progress to identify the optimal dose to achieve and maintain castrate levels of serum total testosterone in men with advanced prostate cancer. For second line hormonal therapy, we are initiating this quarter a Phase II clinical trial evaluating Capesaris in men with castration resistant prostate cancer.”

Clinical Pipeline Updates

Similar Posts:

• Cardio3BioSciences raises €3.1M in non-dilutive funding
• Pfizer acquires Excaliard
• ImaginAb completes Series A financing
• Bring your spreadsheet when you visit the financial therapists couch
• Will government cutbacks curtail recovery in the construction sector?